Temasek leads $65m Series B round for US-based bioscience firm Brightseed

Singapore state investor Temasek has led the $68-million Series B funding round for US-based bioscience company Brightseed, according to an announcement.

The round also saw participation from existing investors including AgFunder, Lewis & Clark AgriFood, S2G Ventures, CGC Ventures, and Germin8.

Brightseed has developed an AI-powered discovery platform, Forager, which systematically identifies natural bioactives and maps their connection to human health benefits.

The company said Forager has mapped more than two million plant compounds, 20 times more than existing scientific literature, and dozens are in various stages of validation across multiple health territories, including metabolic health, digestive health, cognitive health, sugar management, maternal health and immunity.

The new funding will enable Brightseed to advance natural compound discovery and clinical validation.

In September 2020, Brightseed had raised $27 million in funding.

Meanwhile, Temasek has made a spate of venture capital investments in the US market, recently backing cloud security provider Orca, fintech firm iCapital Network, food system innovation player Apeel and private securities marketplace Forge Global.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

This is your last free story for the month. Register to continue reading our content